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Background/aim: To compare the cognitive functions and define the frequency of Alzheimer disease (AD) between participants with
and without age-related macular degeneration (AMD).
Materials and methods: Fifty-nine patients with late-stage AMD (74.3 ± 7.3 years) and 49 age-, sex-, and education-matched control
subjects were compared for the presence of AD according to the guidelines of the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA). Detailed neuropsychological
tests were performed for all subjects.
Results: Neuropsychiatric tests scores were lower in the AMD group than the control group. The frequency of AD was higher in patients
with AMD (40.7% in AMD and 20.4% in control group, P = 0.03), and particularly higher in late dry (nonvascular) AMD (d-AMD)
patients (71.4% in d-AMD and 31.1% in late wet (vascular) AMD, P = 0.007). d-AMD patients performed worse than controls on all
tests. There was also an association between age, sex, and low education and neuropsychiatric tests scores (P < 0.01). However, there was
no association between visual acuity and neuropsychiatric tests scores.
Conclusion: The increased frequency of AD in patients with AMD is significant. This study demonstrated the importance of cognitive
assessment in patients with AMD, particularly in the d-AMD type.
Key words: Alzheimer disease, dementia, age-related macular degeneration, cognitive impairment

1. Introduction
Alzheimer
disease
(AD)
is
an
irreversible
neurodegenerative disease and the most frequent cause
of dementia, characterized by extracellular senile plaques
that are principally formed of β-amyloid peptides,
intracellular accumulation of hyperphosphorylated tau
protein, and neuroﬁbrillary tangles (1). The prevalence
of AD doubles every 5 years over the age of 65 (2). AD
affects more than 38 million people worldwide and
this rate is anticipated to reach 115 million in 2050 (3).
Clinically, it is characterized by memory loss, dementia,
and cognitive impairment. AD causes one of the most
relevant social and health problems because of its social
impact and nonreversible nature (4).
Age-related macular degeneration (AMD) is a
neurodegenerative retinal disease and is the main cause
of legal blindness among people older than 65 years of
age, resulting from the dysfunction and death of retinal
pigment epithelial cells and adjacent photoreceptors in
the macula (5,6). It is reported that 50 million people
* Correspondence: sdndemirci@yahoo.com.tr

worldwide suffer from AMD symptoms and one-third of
them are blind or have severe visual impairment (7,8).
Aging is the main risk factor for both AD and AMD. AD
and AMD share some clinical and pathological characteristics,
comprising oxidative stress and inflammation and impaired
proteasomal and lysosomal function, which cause formation
of intra- and extracellular deposits. In both AD and AMD,
the same destructive aggregated protein deposits occur
primarily in the gray matter of the brain and the macula
of the retina (9–12). It is also suggested that both diseases
share similar environmental risk factors such as systemic
hypertension, cigarette smoking, obesity, unhealthy diet,
and hypercholesterolemia (9,13).
In some studies, cognitive impairment has been
reported in AMD patients (14–16). Since AD also affects
the same age group, at least in some patients this cognitive
impairment may be due to an incipient dementia. As the
aging population increases in developing countries such as
Turkey, knowing if such a relationship exists between AD
and AMD is important.
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The purpose of this study is to compare cognitive
functions and the rate of AD between individuals with and
without AMD, and to analyze cognitive performances of
patients with different pathologies based on AMD types.
2. Materials and methods
2.1. Study population and procedure
The study was conducted at the neurology, ophthalmology,
and psychiatry clinics of a university hospital. Informed
consent was obtained from all subjects according to the
Declaration of Helsinki. The study was approved by the
Süleyman Demirel University Faculty of Medical Sciences
ethics committee.
Fifty-nine patients with late-stage AMD and 49 age-,
sex-, and education-matched healthy subjects were
included in this study. All individuals aged 65 years or
older who had not previously received a diagnosis of AD
were recruited among patients admitted to the outpatient
clinic of the ophthalmology department. AMD patients
who had sufficient visual acuity (VA) (VA ≥ 20/100 in the
better eye) that would not compromise administration
of neuropsychological tests were included in the study.
The exclusion criterion was having neurological and
psychiatric diseases or any other medical conditions that
might affect cognition.
All patients and controls were questioned for basic
information, including demographics, presence of
concomitant diseases, drug usage, and exposure to potential
risk factors for AMD or AD. Following that, all patients
and controls underwent detailed ophthalmological,
neurological, and psychiatric examinations on the same
day.
2.2. Ophthalmic assessment
The ophthalmological examination included the bestcorrected VA, slit lamp biomicroscopy, dilated fundus
examination, and optical coherence tomography. In
addition, retinal photography and angiography with
fluorescein were performed for AMD patients.
The diagnosis of AMD was made according to the
criteria proposed by the Age- Related Eye Disease Study
(16). In the retina examination, soft drusen, retinal
pigment epithelial depigmentation, increased retinal
pigment, geographic atrophy, and signs of exudative
macular degeneration (subretinal hemorrhage, subretinal
fibrous scar, retinal pigment epithelium detachment,
and/or serous detachment of the sensory retina) findings
were used for diagnosis of AMD. The AMD patients were
classified as follows: 1) early AMD: presence of a few (<20)
medium-sized drusen or retinal pigmentary abnormalities;
2) intermediate AMD: at least 1 large drusen, numerous
medium-sized drusen, or geographic atrophy that does not
extend to the center of the macula; 3) late dry (nonvascular)
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AMD (d-AMD): drusen and geographic atrophy extending
to the center of the macula; 4) late wet (vascular) AMD
(w-AMD): choroidal and retinal neovascularization and
its sequelae, such as subretinal fluid, lipid deposition,
hemorrhage, retinal pigment epithelium detachment, and
fibrotic scar. In the patient group, the eyes with lower VA
were used in the statistical analysis (except for 3 patients
with equal VA in both eyes).
2.3. Neuropsychological assessment
All participants were submitted to a detailed
neuropsychological evaluation. Neuropsychological
evaluations were performed by one of the investigators
individually in a single session. All tests were applied in
a predefined order to all patients and controls. First, for
the assessment of mood status, all subjects were given the
Yesavage Geriatric Depression Scale (GDS), which was
developed as a basic screening measure for major and
minor depression in older adults and specifically designed
to assess the presence or absence of depressive symptoms
(17). General cognitive performance was also evaluated
with the Mini-Mental State Examination (MMSE)
(18). Since the education level of the study sample was
predicted to be low, tests requiring reading/writing and
drawing abilities were not included and only tests that
could be administered auditorily/verbally were included
for the assessment. For verbal memory, the Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD)
word list was used (19). Attention and executive functions
were evaluated with digit span (forward and backward)
(20) and CERAD verbal fluency (animals, and K, A, S)
(19). A short version of the Boston naming test (including
equally distributed frequent, intermediate, and rare items,
a total of 15) (19) and the Frontal Assessment Battery were
also administered (19,21). AD was diagnosed according to
the guidelines of the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDSADRDA) (22).
2.4. Statistical analysis
All statistical analyses were performed using SPSS 15.0 for
Windows. Comparisons between the groups for categorical
variables were done with the chi-square test. The normality
of data was assessed via Kolmogorov–Smirnov test. The
independent t-test was used to compare the parametric
variables between the groups. The Pearson correlation
coefficient was used for quantitative relationships.
Analysis of variance (ANOVA) was used to compare the
same independent variable between 3 groups (patients
with d-AMD, patients with w-AMD, and controls).
Bonferroni corrections for post hoc comparisons were
used to compare among these 3 groups’ means at baseline.
The significance level for the tests was 0.05.
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3. Results
The sociodemographic and clinical characteristics of all
subjects are shown in Table 1. The subjects were divided
into 2 groups: patients affected by AMD (n = 59) and
controls (n = 49). The distributions of sex, age, and
duration of education of AMD patients and controls were
similar. Ocular findings in both eyes of AMD patients
are given in Table 2. VA was better in other eyes of latestaged AMD patients (P < 0.001). The AMD group was
also classified as dry type (n = 45) and wet type (n = 14).
Out of the other eyes of 45 w-AMD patients, 4 were wet

(8.9%), 14 were early (31.9%), and 27 were intermediate
(60.0%) type, while in d-AMD patients 1 was early (7.1%)
and 13 were intermediate (92.9%). The mean VA was
lower in d-AMD patients than in w-AMD patients (Table
3). There was an association between age, sex, and short
education duration and neuropsychiatric tests scores (P <
0.01). However, there was no association between visual
acuity and neuropsychiatric tests scores.
According to the guidelines of NINCDS-ADRDA, 24
(40.7%) patients were diagnosed with AD among the 59
patients with AMD. There were 10 (20.4%) subjects who

Table 1. Characteristics of individuals affected by age-related macular degeneration (AMD) and controls.
AMD

Controls

n = 59

n = 49

Mean ± SD
Age (years)

%

Mean ± SD

74.3 ± 7.31

Sex (female)

P-value
%

73.85 ± 5.51
47

0.36
48

0.9

Visual acuity (logMAR)

1.21 ± 0.75

0.39 ± 0.73

<0.001

Education (years)

3.45 ± 2.58

3.63 ± 2.84

0.73

Cigarette smoking

35.6

26.5

0.40

Alcohol

5.10

4.10

0.80

Hypercholesterolemia

30.5

28.6

0.82

Hypertension

66.1

49.0

0.07

Diabetes

23.7

36.7

0.14

Cardiac diseases

25.4

24.5

0.91

Gastrointestinal diseases

18.6

12.2

0.21

Genitourinary diseases

27.1

16.3

0.17

Respiratory diseases

16.9

8.2

0.25

Locomotor diseases

22.0

40.8

0.03

Obesity

30

20

0.21

Sun exposure

71.2

53.1

0.07

Cataract surgery

59.3

42.9

0.08

Light-colored eyes

25.4

8.2

0.02

Meaty diet

27.1

16.3

0.40

SD: Standard deviation.
Table 2. Ocular findings in both eyes of age-related macular degeneration patients.
Visual acuity (logMAR), mean ± SD

Advanced eye

Other eye

1.21 ± 0.76

0.30 ± 0.30

Type of AMD
Early, n (%)

0

15 (25.4)

Intermediate, n (%)

0

40 (67.8)

Late-dry, n (%)

14 (23.7)

0

Late-wet, n (%)

45 (76.3)

4 (6.81)

SD: Standard deviation.
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Table 3. Characteristics of individuals affected by late stage age-related macular degeneration (AMD), dry AMD, and
wet AMD.
d-AMD

w-AMD

n = 14

n = 45

Mean ± SD
Age (years)

%

74.0 ± 10.1

Sex (women)

Mean ± SD

P-value
%

74.4 ± 6.3
78.6

0.86
40

0.01

Visual acuity (logMAR)

1.55 ± 0.36

1.11 ± 0.81

0.006

Education (years)

2.92 ± 3.19

3.62 ± 2.37

0.46

Cigarette smoking

14.3

42.2

0.37

Alcohol

0

6.7

0.99

Hypercholesterolemia

42.9

26.7

0.27

Hypertension

71.4

64.4

0.65

Diabetes

7.1

28.9

0.09

Cardiac diseases

21.4

26.2

0.68

Gastrointestinal diseases

14.3

20.0

0.62

Genitourinary diseases

21.4

28.9

0.56

Respiratory diseases

21.4

15.6

0.61

Locomotor diseases

21.9

22.2

0.93

Obesity

21.7

33.3

0.35

Sun exposure

71.4

71.1

0.99

Cataract surgery

71.9

55.6

0.21

Light-colored eyes

14.3

28.9

0.22

Meaty diet

21.5

28.7

0.85

SD: Standard deviation.

had AD in the control group. The differences between
the groups were statistically significant (P = 0.03). The
frequency of AD was particularly higher in patients
with d-AMD (71.4% in d-AMD and 31.1% in w-AMD,
P = 0.007). Neuropsychological performances of AMD
patients and the control group are shown in Table 4.
MMSE, word list recognition, digit span forward and
total, verbal fluency for letters K and S and K-A-S total,
and FAB scores were lower in the AMD group than the
control group. Neuropsychological test results among the
AMD subtypes and controls are summarized in Table 5.
Patients with d-AMD performed worse than the controls
on all tests and also worse than patients with w-AMD on
all tests except digit span backward.
4. Discussion
In this study, we found that AD frequency was statistically
significantly increased in the AMD group as compared
to the control group. We documented the relationship
between possible cognitive impairment and AMD,
especially d-AMD.
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AMD and AD are both chronic degenerative disorders
affecting the elderly population. AD and AMD have similar
environmental and genetic risk factors (9). In our study,
hypertension, cigarette smoking, obesity, and meaty diet
rates were higher in the AMD group, but we did not find a
statistically significant difference between the groups. Sun
exposure, cataract surgery, and light-colored eyes have
been reported as risk factors for AMD (4). We also found
higher levels of sun exposure, cataract surgery, and lightcolored eyes in the AMD group; light-colored eyes were
statistically significant.
Vision is the most important warning for cognitive
function and poor vision due to AMD may negatively
affect the vision-associated parts of the brain cortex (15).
The association between visual impairment and cognitive
function may be due to the optic nerve and retinal
degeneration. It has been reported that in AD visual
pathways are impaired as compared to in persons without
AD (23). Additionally, optimal cognitive function relies
on processing and recall of information obtained via the
visual sensory system. Thus, performance on assessment
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Table 4. Neuropsychological assessment of individuals affected by age-related macular
degeneration (AMD) and controls.
AMD
n = 59
Mean ± SD

Controls
n = 39
Mean ± SD

P-value

GDS (30)

6.38 ± 4.04

5.93 ± 4.05

0.56

MMSE (30)

24.3 ± 3.88

26.5 ± 3.16

0.002

Encoding (n/30)

12.9 ± 4.77

13.8 ± 3.59

0.29

Recall (n/10)

3.27 ± 2.38

3.65 ± 1.70

0.33

Recognition (n/20)

16.2 ± 2.91

17.4 ± 2.55

0.02

Animals (n/min)

13.7 ± 5.50

15.0 ± 5.66

0.21

K (n/min)

6.08 ± 2.47

8.44 ± 3.27

<0.001

A (n/min)

5.79 ± 2.36

6.73 ± 2.65

0.05

S (n/min)

5.67 ± 2.40

7.10 ± 2.87

0.006

KAS total

17.5 ± 6.93

22.0 ± 7.68

0.002

Forward

5.79 ± 1.95

7.12 ± 1.73

< 0.001

Backward

2.74 ± 1.40

3.28 ± 1.76

0.08

Total

8.54 ± 3.12

10.3 ± 3.12

0.004

Naming (n/15)

11.9 ± 2.12

12.5 ± 1.74

0.12

FAB (18)

12.0 ± 3.24

13.8 ± 2.76

0.004

Verbal memory

Verbal fluency

Digit span

SD: Standard deviation; MMSE: Mini-Mental State Examination; FAB: Frontal
Assessment Battery; GDS: Geriatric Depression Scale.
The scores of neuropsychological tests were adjusted for age, sex, and education.

neuropsychological tests presumably is affected (24). Our
results showed that there was reduced vision and worse
cognitive function in AMD patients, and especially in
d-AMD patients.
Several studies have shown different results for a
potential relationship between AMD and dementia or
cognitive impairment (13–15,25–27). In the Rotterdam
study, Ott et al. (27) analyzed people 75 years and older for
the relation of AMD to cognitive function. They found a
weak association between late AMD and incident AD, but
no association for early AMD and AD. The Blue Mountains
Eye Study found an association between late AMD and
cognitive impairment by using the modified MMSE (27).
However, Wong et al. (26) suggested a weak relationship
between cognitive function and early AMD. In their study,
mean scores were lower for delayed word recall and digit
symbol subtest in the late AMD group but were similar
for word fluency test. Baker et al. (13) found a positive
association between cognitive impairment that depended
on digit symbol substitution test and early AMD. A casecontrol study (15) reported that AMD patients showed

lower global cognition scores than controls. Among
cognitive functions, visuospatial function, verbal memory,
visual memory, and frontal function were impaired in
AMD patients relative to normal controls. The rate of mild
cognitive impairment was higher in AMD patients than
in controls. Geographic atrophy was associated with the
highest risk of mild cognitive impairment and a clinically
significant reduction in MMSE scores (15).
In our study, MMSE, digit span total, verbal fluency for
the letters K and S and K-A-S total, word list recognition,
and FAB total scores were lower in the AMD group than
the control. We found that d-AMD of the AMD types was
associated with the worst cognitive functions and AD. This
is probably because there is slow, progressive degeneration
of photoreceptors and retinal pigment epithelium in
d-AMD and its clinical properties are more similar to the
phenotype of AD than are those of w-AMD (26).
An important factor is that the coexistence of AMD and
AD may cause much worsening in the quality of life in the
elderly. This was contrary to initial expectations that the
depression score would not differ between AMD patients
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Table 5. Neuropsychological assessment of individuals affected by dry age-related macular degeneration (d-AMD),
individuals affected by wet age-related macular degeneration (w-AMD), and controls.
d-AMD
n = 14
Mean ± SD

w-AMD
n = 45
Mean ± SD

Controls
n = 49
Mean ± SD

P (* / ® / #)

GDS (30)

6.42 ± 2.53

6.37 ± 4.43

5.93 ± 4.05

0.84 (0.91 / 0.86 / 0.99)

MMSE (30)

20.71 ± 4.71

25.46 ± 2.80

26.59 ± 3.16

<0.001 (0.001 / 0.19 / 0.008)

9.35 ± 4.81

14.11 ± 4.21

13.83 ± 3.59

0.001 (0.001 / 0.94 / 0.001)

Verbal memory
Encoding (n/30)
Recall (n/10)

1.57 ± 1.91

3.65 ± 1.70

3.80 ± 2.28

0.001 (0.002 / 0.93 / 0.001)

Recognition (n/20)

13.21 ± 3.01

17.17 ± 2.16

17.46 ± 2.55

<0.001 (<0.001 / 0.83 / <0.001)

10.14 ± 5.03

14.84 ± 5.20

15.06 ± 5.66

0.01 (0.009 / 0.97 / 0.01)

Verbal fluency
Animals (n/min)
K (n/min)

4.35 ± 1.73

6.62 ± 2.44

8.44 ± 3.27

<0.001 (<0.001 / 0.006 / 0.02)

A (n/min)

4.14 ± 1.83

6.31 ± 2.29

6.37 ± 2.65

0.003 (0.002 / 0.67 / 0.01)

S (n/min)

3.29 ± 2.05

6.22 ± 2.25

7.10 ± 2.87

<0.001 (<0.001 / 0.21 / 0.01)

KAS total

12.50 ± 5.58

19.13 ± 6.59

22.02 ± 7.68

<0.001 (<0.001 / 0.11 / 0.007)

Digit span
Forward

4.42 ± 1.60

6.22 ± 1.86

7.12 ± 1.73

<0.001 (<0.001 / 0.04 / 0.004)

Backward

1.92 ± 1.26

3.00 ± 1.36

3.28 ± 1.76

0.01 (0.01 / 0.64 / 0.06)

Total

6.35 ± 2.81

9.22 ± 2.92

10.34 ± 3.12

<0.001 (<0.001 / 0.17 / 0.007)

Naming (n/15)

10.07 ± 2.43

12.12 ± 1.97

12.53 ± 1.74

<0.001 (<0.001 / 0.98 / <0.001)

FAB (18)

9.57 ± 3.13

12.84 ± 2.89

13.81 ± 2.76

<0.001 (<0.001 / 0.23 / 0.001)

SD: Standard deviation; MMSE: Mini-Mental State Examination; FAB: Frontal Assessment Battery; GDS: Geriatric
Depression Scale
The scores of neuropsychological test were adjusted for age, sex, and education.
P: P-value for ANOVA.
*: P-value between controls and d-AMD.
®: P-value between controls and w-AMD.
#
: P-value between d-AMD and w-AMD.

and normal controls. Whitson et al. (28) reported that the
comorbidity of visual and cognitive impairment leads to a
higher risk of disability than each of impairment alone.
The important limitation of our study is the relatively
small sample. Additionally, although we included AMD
patients who had sufficient VA (VA ≥ 20/100 in the better
eye) to allow for conducting neuropsychological tests in

the study, reduced vision may have influenced the success
of neuropsychological tests.
In conclusion, this study showed a possible association
of AMD, and especially d-AMD type, with cognitive
impairment and AD. The risk of cognitive impairment
and AD should also be considered in patients with AMD,
particularly in the d-AMD type.
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